| Name | ZL0420 |
| Description | ZL0420 is a potent and selective bromodomain-containing protein 4 (BRD4) inhibitor with nanomolar binding affinities to the bromodomains (BDs) of BRD4, exhibiting IC50 values of 27 nM against BRD4 BD1 and 32 nM against BRD4 BD2. |
| In vitro | ZL0420 effectively binds to the acetyl-lysine (KAc) binding pocket of BRD4, establishing essential interactions, notably critical hydrogen bonds directly with Asn140 and indirectly with Tyr97 through a water molecule. It demonstrates submicromolar efficacy in suppressing the TLR3-dependent innate immune gene program, including ISG54, ISG56, IL-8, and Groβ genes in cultured human small airway epithelial cells (hSAECs), with IC50 values ranging from 0.49 to 0.86 μM [1]. |
| In vivo | ZL0420 demonstrates potent efficacy in reducing airway inflammation with low toxicity in a mouse model, almost completely blocking the significant accumulation of neutrophils around small and medium-sized airways induced by poly(I:C) administration [1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (6.75 mM), Sonication is recommended.
DMSO : 59 mg/mL (199.11 mM), Sonication is recommended.
|
| Keywords | ZL-0420 | ZL0420 | ZL 0420 | Inhibitor | inhibit | immune response genes | EpigeneticReaderDomain | Epigenetic Reader Domain | bromodomains | BRD4 | BET | airway inflammation | (E/Z)-ZL0420 |
| Inhibitors Related | ABBV-744 | SNDX-5613 | CeMMEC1 | 3-methyl-1,2,3,4-tetrahydroquinazolin-2-one | (+)-JQ-1 | J-147 | 5-Ph-IAA | Curcumin | dBET6 | Naphthol AS-E | JQ-1 (carboxylic acid) | Bisdemethoxycurcumin |
| Related Compound Libraries | Histone Modification Compound Library | Bioactive Compound Library | Epigenetics Compound Library | Inhibitor Library | PPI Inhibitor Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
United States
